Insmed Incorporated (NASDAQ:INSM) Shares Sold by CenterBook Partners LP

CenterBook Partners LP cut its holdings in shares of Insmed Incorporated (NASDAQ:INSM) by 88.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 9,391 shares of the biopharmaceutical company’s stock after selling 71,945 shares during the quarter. CenterBook Partners LP’s holdings in Insmed were worth $648,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of INSM. Captrust Financial Advisors lifted its position in shares of Insmed by 40.9% during the third quarter. Captrust Financial Advisors now owns 6,280 shares of the biopharmaceutical company’s stock worth $458,000 after purchasing an additional 1,824 shares during the last quarter. Orion Portfolio Solutions LLC grew its holdings in Insmed by 48.5% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 28,087 shares of the biopharmaceutical company’s stock worth $2,050,000 after buying an additional 9,170 shares in the last quarter. MML Investors Services LLC increased its holdings in shares of Insmed by 36.2% during the third quarter. MML Investors Services LLC now owns 22,201 shares of the biopharmaceutical company’s stock valued at $1,621,000 after purchasing an additional 5,897 shares during the period. M&T Bank Corp acquired a new position in Insmed during the 3rd quarter valued at about $218,000. Finally, Geode Capital Management LLC increased its stake in shares of Insmed by 4.7% during the third quarter. Geode Capital Management LLC now owns 3,813,384 shares of the biopharmaceutical company’s stock valued at $278,432,000 after acquiring an additional 172,664 shares during the period.

Insider Transactions at Insmed

In related news, insider Martina M.D. Flammer sold 1,384 shares of the company’s stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $68.72, for a total transaction of $95,108.48. Following the sale, the insider now owns 100,165 shares in the company, valued at approximately $6,883,338.80. This represents a 1.36 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Roger Adsett sold 1,457 shares of the firm’s stock in a transaction that occurred on Tuesday, January 14th. The shares were sold at an average price of $68.72, for a total value of $100,125.04. Following the completion of the transaction, the chief operating officer now owns 146,082 shares of the company’s stock, valued at approximately $10,038,755.04. This represents a 0.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 499,613 shares of company stock valued at $39,569,355 in the last ninety days. 4.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on INSM shares. Wells Fargo & Company upped their target price on Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a report on Wednesday, February 19th. Bank of America boosted their price target on shares of Insmed from $92.00 to $96.00 and gave the company a “buy” rating in a report on Thursday, March 20th. JPMorgan Chase & Co. increased their price objective on Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a report on Friday, February 7th. Stifel Nicolaus cut their target price on Insmed from $97.00 to $96.00 and set a “buy” rating on the stock in a report on Friday, February 21st. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $100.00 price target on shares of Insmed in a research report on Wednesday, March 19th. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $94.00.

Insmed Price Performance

INSM stock opened at $68.57 on Friday. The stock has a 50-day moving average price of $76.20 and a two-hundred day moving average price of $73.64. Insmed Incorporated has a 1 year low of $21.92 and a 1 year high of $84.91. The stock has a market cap of $12.47 billion, a PE ratio of -12.27 and a beta of 1.07. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). The firm had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. Equities analysts forecast that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.